Best Practice & Research Clinical Haematology
Volume 19, Issue 3 , Pages 571-593 , September 2006

Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined

  • Michelle A. Elliott MD (Assistant Professor of Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 507 284 2865; Fax: +1 507 266 4972.

References 

  1. In:  Jaffe ES,  N. H,  Vardiman JW editor. World Health Organization classification of Tumours: Pathology and Genetics of Tumours and Lymphoid Tissue. Lyon, France: IARC Press; 2001;
  2. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292–2302
  3. You W, Weisbrot IM. Chronic neutrophilic leukemia. Report of two cases and review of the literature. American Journal of Clinical Pathology. 1979;72(2):233–242
  4. Reilly JT. Chronic neutrophilic leukaemia: a distinct clinical entity?. British Journal of Haematology. 2002;116(1):10–18
  5. Bohm J, et al. Evidence of clonality in chronic neutrophilic leukaemia. Journal of Clinical Pathology. 2003;56(4):292–295
  6. Tuohy E. A case of splenomegaly with polymorphonuclearneutrophil hyperleukocytosis. American Journal of Medical Science. 1920;160:18–25
  7. Harris NL, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology. 1997;17(12):3835–3849
  8. Bennett JM, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French–American-British cooperative leukaemia group. British Journal of Haematology. 1994;87(4):746–754
  9. Ben-Tal OmR, Windor A, Eldor A. Chronic neutrophilic leukemia(CNL): a true leukemia? a new classification. Blood. 1997;90:291b;[abstract]
  10. Zoumbos NC, Symeonidis A, Kourakli-Symeonidis A. Chronic neutrophilic leukemia with dysplastic features. A new variant of the myelodysplastic syndromes. [comment]. Acta Haematologica. 1989;82(3):156–160
  11. Lugassy G, Farhi R. Chronic neutrophilic leukemia associated with polycythemia vera. [comment]. American Journal of Hematology. 1989;31(4):300–301
  12. Zittoun R, et al. Chronic neutrophilic leukemia. A study of four cases. Annals of Hematology. 1994;68(2):55–60
  13. Standen GR, et al. Chronic neutrophilic leukemia and multiple myeloma. An association with lambda light chain expression. Cancer. 1990;66(1):162–166
  14. Elliott MA, et al. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19:313–317
  15. Storek J. Chronic neutrophilic leukemia: case report documenting the absence of bcr-abl rearrangement. American Journal of Hematology. 1992;41(4):304
  16. Ohtsuki T, et al. Elevated neutrophil function in chronic neutrophilic leukemia. American Journal of Hematology. 1992;41(1):50–56
  17. Kwong YL, Cheng G. Clonal nature of chronic neutrophilic leukemia. [comment]. Blood. 1993;82(3):1035–1036
  18. Meyer S, et al. Successful alpha-2b-interferon therapy for chronic neutrophilic leukemia. American Journal of Hematology. 1993;43(4):307–309
  19. Hasle H, et al. Chronic neutrophil leukaemia in adolescence and young adulthood. British Journal of Haematology. 1996;94(4):628–630
  20. Matano S, et al. Deletion of the long arm of chromosome 20 in a patient with chronic neutrophilic leukemia: cytogenetic findings in chronic neutrophilic leukemia. American Journal of Hematology. 1997;54(1):72–75
  21. Yanagisawa K, et al. Neoplastic involvement of granulocytic lineage, not granulocytic-monocytic, monocytic, or erythrocytic lineage, in a patient with chronic neutrophilic leukemia. American Journal of Hematology. 1998;57(3):221–224
  22. Terre C, et al. A case of chronic neutrophilic leukemia with deletion (11)(q23). Cancer Genetics and Cytogenetics. 1999;110(1):70–71
  23. Kojima K, et al. Familial occurrence of chronic neutrophilic leukaemia. British Journal of Haematology. 1999;105(2):428–430
  24. Frank MB, Norwood TH, Willerford DM. Chimeric del20q in a case of chronic neutrophilic leukemia. American Journal of Hematology. 2000;64(3):229–231
  25. Elliott MA, et al. Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study. Leukemia. 2001;15(1):35–40
  26. Willard RJ, et al. Leukemia cutis in a patient with chronic neutrophilic leukemia. Journal of the American Academy of Dermatology. 2001;44(supplement 2):365–369
  27. Piliotis E, Kutas G, Lipton JH. Allogeneic bone marrow transplantation in the management of chronic neutrophilic leukemia. Leukemia and Lymphoma. 2002;43(10):2051–2054
  28. Kobayashi S, et al. Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia. Journal of Biological Chemistry. 2002;277(37):33968–33977
  29. Bohm J, Schaefer HE. Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease. Journal of Clinical Pathology. 2002;55(11):862–864
  30. TD, C.J.a.C. . In:  Hoffman R, et al. editor. Disorders of Phagocyte Function and Number. Haematology: Basic Principles and Practice. 3rd edn. London: Churchill Livingstone; 2000;p. 720–761[chapter 41]
  31. Kasuga I, et al. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer. 2001;92(9):2399–2405
  32. Ganti AK, Potti A, Mehdi S. Uncommon syndromes and treatment manifestations of malignancy: Case 2. Metastatic non-small-cell lung cancer presenting with leukocytosis. Journal of Clinical Oncology. 2003;21(1):168–170
  33. Rajkumar SV, et al. Current therapy for multiple myeloma. [see comment]. Mayo Clinic Proceedings. 2002;77(8):813–822
  34. Ito T, et al. Chronic neutrophilic leukemia associated with monoclonal gammopathy of undetermined significance. Acta Haematologica. 1996;95(2):140–143
  35. Cehreli C, et al. Coexistence of chronic neutrophilic leukemia with light chain myeloma. Acta Haematologica. 1994;91(1):32–34
  36. Rovira M, et al. Chronic neutrophilic leukaemia preceding for seven years the development of multiple myeloma. Acta Haematologica. 1990;83(2):94–95
  37. Reeder TL, et al. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood. 2003;101(5):1981–1983
  38. Standen GR, Steers FJ, Jones L. Clonality of chronic neutrophilic leukaemia associated with myeloma: analysis using the X-linked probe M27 beta. Journal of Clinical Pathology. 1993;46(4):297–298
  39. Stevenson JP, Schwarting R, Schuster SJ. Analysis of clonality using X-linked polymorphisms in a patient with multiple myeloma and myelofibrosis. American Journal of Hematology. 1998;59(1):79–82
  40. Imbert MVJ, Pierre R. Essential thrombocythemia. World Health Organization classification of Tumours: Pathology and Genetics of Tumours and Lymphoid Tissue. 2001;p. 39–41
  41. Ota S, et al. Evolution to acute myeloblastic leukemia from chronic neutrophilic leukemia with dysplastic features in granulocytic lineage. Acta Haematologica. 2000;104(4):207–211
  42. Pascucci M, et al. Chronic neutrophilic leukemia evolving from a myelodysplastic syndrome. Acta Haematologica. 1997;98(3):163–166
  43. Froberg MK, et al. Demonstration of clonality in neutrophils using FISH in a case of chronic neutrophilic leukemia. Leukemia. 1998;12(4):623–626
  44. Merlat A, Fontaney-Roupie VF, et al. Clonal evolution from a 5q- myelodysplastic syndrome to a chronic neutrohilic leukemia. Blood. 2000;96:262b;[abstract]
  45. Yamamoto K, et al. Acquired gain of an X chromosome as the sole abnormality in the blast crisis of chronic neutrophilic leukemia. Cancer Genetics and Cytogenetics. 2002;134(1):84–87
  46. Hirayama Y, et al. [A case of chronic neutrophilic leukemia accompanied with severe bone marrow fibrosis which was effectively treated by hydroxyurea]. Rinsho Ketsueki—Japanese Journal of Clinical Hematology. 1994;35(11):1329–1334
  47. Higuchi T, et al. Transition of polycythemia vera to chronic neutrophilic leukemia. Leukemia and Lymphoma. 1999;33(1-2):203–206
  48. Noguchi T, et al. Severe bleeding tendency caused by leukemic infiltration and destruction of vascular walls in chronic neutrophilic leukemia. International Journal of Hematology. 2001;74(4):437–441
  49. Tefferi A. Myelofibrosis with myeloid metaplasia. [see comment]. New England Journal of Medicine. 2000;342(17):1255–1265
  50. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clinic Proceedings. 2003;78(2):174–194
  51. Thiele J, et al. Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF)—a clinicopathological study. Leukemia. 1999;13(11):1741–1748
  52. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343–3356
  53. Quackenbush RC, et al. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases. Blood. 2000;95(9):2913–2921
  54. Pane F. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)[comment][erratum appears in Blood Jun 1;89(11):4244]. Blood. 1996;88(7):2410–2414
  55. Kurzrock R, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. Journal of Clinical Oncology. 2001;19(11):2915–2926
  56. Wilson G, et al. BCR-ABL transcript with an e19a2 (c3a2) junction in classical chronic myeloid leukemia. [comment]. Blood. 1997;89(8):3064
  57. Briz M, et al. Typical chronic myelogenous leukemia with e19a2 junction BCR/ABL transcript. Blood. 1997;90(12):5024–5025
  58. Ohsaka A, et al. Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCR-ABL). [see comment]. Internal Medicine. 2002;41(12):1183–1187
  59. Yamagata T, et al. Elevated platelet count features the variant type of BCR/ABL junction in chronic myelogenous leukaemia. British Journal of Haematology. 1996;94(2):370–372
  60. Saglio G, et al. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1990;76(9):1819–1824
  61. Kojima K, et al. Additional translocation (8;21)(q22;q22) in a patient with Philadelphia-positive chronic myelogenous leukaemia in the blastic phase. [see comment]. British Journal of Haematology. 1999;106(3):720–722
  62. Verstovsek S, et al. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer. 2002;94(9):2416–2425
  63. Elliott MA, Tefferi DG, Hanson CA. Chronic Neutrophilic Leukemia (CNL): a long-term clinical, pathologic, and cytogenetic study. Leukemia. 2001;94(15):35–41
  64. Bench AJ, et al. Molecular genetics and cytogenetics of myeloproliferative disorders. Baillieres Clinical Haematology. 1998;11(4):819–848
  65. Greenberg P, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088
  66. Grimwade D, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties. Blood. 1998;92(7):2322–2333
  67. Asimakopoulos FA, Green AR. Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders. British Journal of Haematology. 1996;95(2):219–226
  68. Tefferi A, et al. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. British Journal of Haematology. 2001;113(3):763–771
  69. Martin PJ, et al. Involvement of the B-lymphoid system in chronic myelogenous leukaemia. Nature. 1980;287(5777):49–50
  70. Tefferi A, et al. Fluorescent in situ hybridization studies of lymphocytes and neutrophils in chronic granulocytic leukemia. Cancer Genetics and Cytogenetics. 1995;83(1):61–64
  71. Raskind WH, et al. Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia. Journal of Clinical Investigation. 1985;75(4):1388–1390
  72. Busque L, et al. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood. 1996;88(1):59–65
  73. Champion KM, et al. Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. British Journal of Haematology. 1997;97(4):920–926
  74. Bennett JM, et al. Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology. 1982;51(2):189–199
  75. Voglova J, et al. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia—distinct subgroups or two stages of the same disease?. Leukemia Research. 2001;25(6):493–499
  76. Onida F, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99(3):840–849
  77. Fenaux P, et al. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. Journal of Clinical Oncology. 1988;6(9):1417–1424
  78. Catalano L, et al. Prognosis of chronic myelomonocytic leukemia. Haematologica. 1996;81(4):324–329
  79. Nosslinger T, et al. Dysplastic versus proliferative CMML—a retrospective analysis of 91 patients from a single institution. Leukemia Research. 2001;25(9):741–747
  80. Goasguen JE, et al. Prognostic factors of myelodysplastic syndromes—a simplified 3-D scoring system. Leukemia Research. 1990;14(3):255–262
  81. Stark AN, et al. Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML). British Journal of Cancer. 1987;56(1):59–63
  82. Emanuel PD. Juvenile myelomonocytic leukemia. Current Hematology Reports. 2004;3(3):203–209
  83. anonymous . Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? a prospective multicenter study of 100 patients. Groupe Francais de Cytogenetique Hematologique. Cancer Genetics and Cytogenetics. 1991;55(1):57–65
  84. Fenaux P, et al. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. British Journal of Haematology. 1991;77(4):497–501
  85. Catalano L, et al. Prognosis of chronic myelomonocytic leukemia. Haematologica. 1996;81(4):324–329
  86. Strupp C, et al. Pericardial effusion in chronic myelomonocytic leukemia (CMML): a case report and review of the literature. Leukemia Research. 2000;24(12):1059–1062
  87. Bourantas KL, et al. Pleural effusion in chronic myelomonocytic leukemia. Acta Haematologica. 1998;99(1):34–37
  88. Aul C, et al. Fatal hyperleukocytic syndrome in a patient with chronic myelomonocytic leukemia. Leukemia Research. 1997;21(3):249–253
  89. Stemmler J, et al. Leukapheresis in chronic myelomonocytic leukemia with leukostasis syndrome: elevated serum lactate levels as an early sign of microcirculation failure. Leukemia and Lymphoma. 2002;43(7):1427–1430
  90. Germing U, Kundgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leukemia and Lymphoma. 2004;45(7):1311–1318
  91. Germing U, Strupp CA, Gattermann N. New prognostic parameters for chronic myelomonocytic leukemia. Blood. 2002;100(2):731–732
  92. Germing U, et al. Problems in the classification of CMML—dysplastic versus proliferative type. Leukemia Research. 1998;22(10):871–878
  93. Onida F, Kantarjian H, Ball G, et al. The dysplastic versusproliferative classificationdilemma of chronic myelomonocytic leukemia: a retrospective single institution analysis of 273 patients. Blood. 2001;98(suppliment 1):2607
  94. Gonzalez-Medina I, et al. Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. Leukemia Research. 2002;26(9):821–824
  95. Onida F, Beran M. Chronic myelomonocytic leukemia: myeloproliferative variant. Current Hematology Reports. 2004;3(3):218–226
  96. Worsley A, et al. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. British Journal of Haematology. 1988;68(1):17–21
  97. Aul C, et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6(1):52–59
  98. Breccia M, Latagliata R, Mengarelli A, et al. Prognostic factors in myelodysplastic and Myeloproliferatve types of chronic myelomonocytic leukemia: a retrospctive analysis of 83 patients from a single institution. Haematologica. 2004;89(7):866–868
  99. Golub TR, et al. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77(2):307–316
  100. Ross TS, et al. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood. 1998;91(12):4419–4426
  101. Carroll M, et al. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(25):14845–14850
  102. Gunby RH, et al. Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia. Haematologica. 2003;88(4):408–415
  103. Apperley JF, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. New England Journal of Medicine. 2002;347(7):481–487
  104. Miyauchi J, et al. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood. 1994;83(8):2248–2254
  105. Loh ML, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 2004;103(6):2325–2331
  106. Tartaglia M, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature Genetics. 2003;34(2):148–150
  107. Loh ML, Martinelli S, Cordeddu V, et al. Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia Research. 2005;29:459–462
  108. Wattel E, et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe francais des myelodysplasies and European CMML group. Blood. 1996;88(7):2480–2487
  109. Beran M, et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia and Lymphoma. 1998;31(5-6):521–531
  110. Beran M, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. Journal of Clinical Oncology. 1999;17(9):2819–2830
  111. Beran M, Cortes OM. Chemotherapy of increasing intensity in the treatment of chronic myelomonocytic leukemia. Blood. 2001;98:624a
  112. Castro-Malaspina H, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood. 2002;99(6):1943–1951
  113. Zang DY, et al. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. British Journal of Haematology. 2000;110(1):217–222
  114. Kroger N, et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the chronic leukaemia working party of the European group for Blood and Marrow Transplantation (EBMT). British Journal of Haematology. 2002;118(1):67–73
  115. Mittal P, et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplantation. 2004;33(10):1005–1009
  116. Ho AY, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood. 2004;104(6):1616–1623

PII: S1521-6926(05)00098-8

doi: 10.1016/j.beha.2005.07.012

Best Practice & Research Clinical Haematology
Volume 19, Issue 3 , Pages 571-593 , September 2006

Article Tools